How hot are antibody-drug conjugates?
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
Astra starts a pivotal lung cancer combo
Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.
AACR 2024 – BioNTech sees pancreatic promise amid neoantigen delays
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
Astra goes early in small cell
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
Merck makes haste to catch up in KRAS
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
